Mild Respiratory Distress

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Mild Respiratory Distress trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06658535

A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosi…

Canada18 participantsStarted 2025-03-13

Treatment: dodecafluoropentane (0.025 mL/kg), dodecafluoropentane (0.032 mL/kg)

All recent trials (20 shown)

TerminatedPhase 2

NCT04305457

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in D…

United States62 participantsStarted 2020-03-21

Treatment: Nitric Oxide

Not Yet RecruitingPhase 1

NCT07449572

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS

This Phase 1/2A, randomized, double-blind study will evaluate the safety, tolerability, and pharmacokinetics (PK) of HT31-1 (hCitH3-mAb) in healthy adult volunt…

United States24 participantsStarted 2026-03

Treatment: HT31-1, Saline (0.9%, sterile, for infusion)

Mild Respiratory Distress

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

All recent trials (20 shown)

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

All recent trials (20 shown)

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS

Respiratory Transition Without Continuous Positive Airway Pressure

Post-Market Study of Low-flow ECCO2R Using PrismaLung+

Early Kangaroo Care vs. Standard Neonatal Practices: Impact on Survival and Outcomes in Preterm Infants

Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome

Expanded Access to Zofin for Patients With COVID-19

Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress

Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.

Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe

Roflumilast as add-on Therapy in Early Cases of ARDS

A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory…

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Mild Hypothermia for COVID-19 ARDS

Physiological Effects of a New Interface on Lung Ventilation and Gas Distribution

Effects of a New Interface for NIV on Respiratory Drive

Low-Flow CO2 Removal for Mild to Moderate ARDS With PRISMALUNG

HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP for Respiratory Distress Syndrome of Prematurity